Iambic Therapeutics
Founded 2019 · CIK 0001997038 · Biotech · Private
AI-powered drug discovery platform that identifies and optimizes therapeutic candidates
iambic.ai →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $323M
- 5 Form D · Sep 2026
- 1 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 1 granted · 39 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20232024202520262027
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $103,230,763 | |
| Private capital raised | Form D · SEC | $26,874,991 | |
| Private capital raised | Form D · SEC | $99,269,270 | |
| Private capital raised | Form D · SEC | $27,769,668 | |
| Private capital raised | Form D · SEC | $65,965,000 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1741 | Superluminal Medicines | — | $116M |
| 1742 | Gossamer Bio | — | $728M |
| 1743 | PHI OPTICS INC | — | $450K |
| 1744 | Iambic Therapeutics | — | $323M |
| 1745 | AVT, Inc. | — | $170K |
| 1746 | INFINIFLUIDICS INC | — | — |
| 1747 | Airway Therapeutics, LLC | — | $54M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Jishnu BhattacharjeeDirector
- Neil JosephsonExecutive Officer
- Fred ManbyDirector · Executive Officer
- Thomas MillerDirector · Executive Officer
- Pete OlsonExecutive Officer
- Evan RachlinDirector
- William RastetterDirector
- Michael SecoraExecutive Officer
- Shalini SharpDirector
- Mary TagliaferriDirector
- Tabbert TengExecutive Officer
- R. Jacob VogelsteinDirector
- Kurt von EmsterDirector
- Chao ZhangExecutive Officer
Patents
- Kif Modulator Compounds And Methods Of Useapplication
- Kif Modulator Compounds And Methods Of Useapplication
- Doses And Regimens Of HER2 Inhibitorsapplication
- Solid State Forms Of HER2 Inhibitorsapplication
- Compounds And Methods For Modulating HER2application
- Methods Of Use For Aza-quinazoline Compoundsapplication
- Compounds And Methods For Modulating HER2granted
- Compounds And Methods For Modulating HER2application
- Quinazoline Compounds And Methods Of Useapplication
- Aza-quinazoline Compounds And Methods Of Useapplication
- Systems and Methods for Determining Molecular Properties with Atomic-Orbital-Based Featuresapplication
- Doses And Regimens Of HER2 Inhibitorsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.